HEARTSEED
Heartseed , a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), today announced it has raised 4 Billion-yen (approx. $37 Million) at Series C round, bringing its total financial backing to 8.2 Billion yen (approx. $75 Million) since its foundation in 2015.
New investors are UTokyo Innovation Platform Co. (UTokyo IPC), Medical Incubator Japan, Keio Innovation Initiative (KII), and Sumitomo Mitsui Trust Investment. Among the existing investors, SBI Group, Nissay Capital, SMBC Capital, Medipal Holdings, and Itochu Chemical Frontier participated in this round.
Heartseed will use the new funds to accelerate the initiation of global clinical trial of HS-001 for HF as well as to confirm its proof of concept in Phase 1/2 LAPiS study in Japan. Additionally, Heartseed will also examine a less invasive administration such as transendocardial injection using a catheter.
“Heartseed has made a strong progress in our research and development of our cardiac remuscularization therapy, as proved by the clearance of clinical trial application of Phase I/II LAPiS Study by the Japanese Pharmaceutical and Medical Agency and many awards we received.” said Professor. Keiichi Fukuda, co-founder and CEO at Heartseed. “The commitment from both new and existing investors in this round is a strong validation of our technology and strategic vision. With their support, we look forward to accelerating our development to deliver potentially curative therapy for heart failure across the globe.”
About HS-001
Heartseed's lead pipeline, HS-001, is allogeneic iPSC-derived, highly purified ventricular cardiomyocyte spheroids. By forming micro-tissue-like spheroids, retention rate and viability of cell transplant are improved. The spheroids are transplanted using a special administration needle (SEEDPLANTER®) and guide adapter developed for safe and efficient administration of the spheroids into the myocardial layer of the heart.
The expected mechanism of action is that the transplanted cardiomyocytes electrically couple with the patient's myocardium to improve cardiac output by remuscularization, and secretion of angiogenic factors to form new blood vessels around the transplant site (neovascularization).
The review of the Clinical Trial Application of a phase I/II clinical trial (LAPiS Study) evaluating the safety and efficacy of HS-001 for the treatment of heart failure caused by ischemic heart disease in Japan was successfully completed in March 2021 by Japan's Pharmaceutical and Medical Devices Agency.
For details: http://www.heartseed.jp/en/index.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20210611005010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cooler Master Expands the MasterFrame Series with the Compact and Modular MasterFrame 400 Mesh12.11.2025 13:07:00 CET | Press release
The New PC Case Combines Modular Flexibility with a Clean Design for Easy Builds and Polished Final Look Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced the MasterFrame 400 Mesh, a compact PC case that brings the signature MasterFrame design language to a more accessible, desk-friendly format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112507322/en/ MasterFrame 400 Mesh shown with V4 3DHP air cooler. The MasterFrame 400 Mesh delivers FreeForm 2.0 modularity in a simplified build experience. It offers dual orientation for vertical or horizontal setups, repositionable brackets, and mesh-optimized airflow so builders can tailor layout and thermals with confidence. The result is a compact footprint that still supports serious hardware. The case is engineered for Micro-ATX and Mini-ITX systems and supports high-performance components without compromise. Builders can install GPU
IonQ to Highlight Real-World Quantum Applications at Web Summit 202512.11.2025 13:05:00 CET | Press release
IonQ’s Dr. Chris Ballance to speak on how fidelity breakthroughs are accelerating practical use cases and quantum advantage IonQ (NYSE: IONQ), the world’s leading quantum company, today announced its participation in Web Summit 2025, one of the largest technology events in Europe. IonQ’s President of Quantum Computing and co-founder of Oxford Ionics, Dr. Chris Ballance, is scheduled to speak during the conference’s AI Summit on Thursday, November 13, 2025, at 10:30 AM local time. The AI Summit session, “Quantum Without Compromise: The Race to Real-world Applications,” will be moderated by technology journalist, Mary-Ann Russon. The discussion will focus on IonQ’s recent breakthroughs in quantum gate fidelity and how these advancements underpin the company’s roadmap toward fault-tolerant systems. Dr. Ballance will also share how these engineering accomplishments translate into quantum computing’s growing impact across industries. “We’re at a pivotal moment where breakthroughs in quantum
Ananda Scientific and Benta Sign Memorandum on Advancing Treatments for PTSD12.11.2025 13:04:00 CET | Press release
Ananda Scientific Inc., a clinical-stage drug development company advancing innovative therapies for high-impact neuropsychiatric disorders, today announced the signing of a Memorandum of Understanding (MOU) with Benta SAS. The MOU expresses the parties’ intent to explore a potential collaboration focused on accelerating the development and future availability of a new treatment for Post-Traumatic Stress Disorder (PTSD) in Europe and the Middle East/North Africa (MENA) region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112416172/en/ PTSD is a chronic and debilitating condition that affects millions of people worldwide. Despite its significant prevalence and devastating impact on patients, families, and communities, there has been no new approved drug for PTSD in over two decades — underscoring a critical unmet medical need. As part of its clinical development pipeline, Ananda Scientific is currently advancing Nantheia
Global Airline Reliability Improves in October, Led by Asia-Pacific as North America Faces Operational Pressures; Cirium Analysis12.11.2025 13:00:00 CET | Press release
Cirium, the world’s most trusted source of aviation analytics, has published its October 2025 On-Time Performance (OTP) Report, covering more than 370,000 flights with 99.8% global coverage. The data indicates a 26% reduction in global cancellations compared with September, reflecting improved operational stability across the commercial aviation network. The results also highlight distinct regional dynamics shaping airline performance worldwide. Asia-Pacific carriers led the recovery, cutting flight cancellations by 43% as airlines across Japan, South Korea, and the Philippines strengthened network performance and capacity. Notably, the world’s top-performing airports in October — Harbin Taiping and Changchun Longjia in China, and Kaohsiung International in Taiwan — were all located in the region, underscoring its continued operational gains and steady recovery momentum. North American operations showed greater operational strain, with flight cancellations rising by about 12.6% month o
New Study Further Validates Environmental Benefits of Floor Refinishing Compared to Replacement12.11.2025 12:00:00 CET | Press release
Renovation of hard flooring surfaces, such as wood and resilient, saves up to 92 percent in CO2 emissions and up to 98 percent in energy usage A recent report and lifecycle assessment (LCA) conducted by IVL Swedish Environmental Research Institute confirms refinishing hard flooring surfaces, including wood, vinyl and linoleum, is more sustainable for the environment than replacing the flooring surfaces. This new study, which was conducted for the German market, is the next step of research inspired from a previous 2019 study conducted in Sweden. Both studies aim to evaluate the environmental impact of replacing a worn, damaged or outdated flooring surface compared to refinishing the flooring surface which may include sanding, finishing, staining, or painting. Bona, a global, family-owned company that supplies products for installing, renovating, maintaining, and restoring premium floors, commissioned this new study to build on the findings from a 2019 Swedish study. The new research fo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom